Are There Alternative or Complementary Biomarkers?
Yes, there are alternative and complementary biomarkers that can be used alongside PD-L1 to better predict responses to immunotherapy. These include tumor mutational burden (TMB), microsatellite instability (MSI), and gene expression profiles. Combining these biomarkers can provide a more comprehensive understanding of the tumor's behavior and its interaction with the immune system.
